# Agenus share price today (Agenus Inc., AGEN)

> Agenus Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. AGEN · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/agen

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $6.97 (+75.1% in a year)
- P/E: 2.8×, against its own history
- Revenue (Jun 2026): $34.5 M (+34.4% on a year ago)
- Profit (Jun 2026): −$604 K
- Operating margin: 32.7% (+98.0 points on a year ago)
- ROE: 0%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Agenus share price today? Agenus Inc.'s share price was $6.97 at the close on 4 November 2026. That is 40.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $9, and at that close it sat 72% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 1 week in a row. Over the last 1 year the share price moved −1% while the S&P 500 moved +18%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Agenus pay? Agenus Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Agenus on? Agenus is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Agenus profitable? Agenus Inc. posted a net loss of $604 K in the Jun 2026 quarter. The full FY25 year was a loss of $101 K. That loss is 1.7% of the quarter's revenue. The same quarter a year earlier lost $28.0 M. 10 of the last 12 reported quarters were loss-making. ## How much revenue does Agenus make, and is it growing? Agenus Inc. reported $34.5 M of revenue in the Jun 2026 quarter, +34.4% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 4 years it has grown −21.2% a year on average. The last full year, FY25, came in at $114 M. The last four reported quarters add to $133 M. FY25 revenue was $114 M, +10.4% on the year before. Recent pace: the last four quarters grew +30.6% on average, against −21.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +30.5%, against −8.8% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Agenus keep? Agenus Inc.'s operating margin was 32.7% in the Jun 2026 quarter, 98.0 percentage points higher than the same quarter a year ago. Across 5 years it has been between −183.9% and 12.6%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +98.0 percentage points on the year while gross margin changed +62.1 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Agenus' profit turning into cash? Agenus Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $77.2 M of cash, against −$101 K of profit. After $6.0 K of spending on assets, free cash was −$77.2 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Agenus' cash go? Agenus Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $10.5 M on assets over the last 3 years. Averaged over those years that is 3.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $10.5 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Agenus' P/E ratio, and how does it compare with its own history? Agenus Inc.'s P/E is 2.8×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Agenus business getting better or worse? Agenus Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Agenus earn on its capital? Agenus Inc. earned a ROE of 0% in FY25. That is up from a low of −50% in FY21. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a −0.1% net margin and 0.50× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −0.1% net margin × 0.50× asset turnover × −0.82× leverage (assets divided by equity) ≈ 0.0% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. ## Does Agenus have too much debt? Agenus Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 1.23 in FY21 to −0.20 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Agenus shareholding pattern? 17.4% of Agenus Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 6.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Agenus from balance-sheet trouble? For Agenus Inc., the Z-score is −16.78. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −16.78 is inside the danger zone, so the balance sheet is a real risk. ## How does Agenus rank in its industry? There is no score against its industry: Agenus Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Agenus compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Agenus in size? Agenus is the 168th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Alector, Inc., Benitec Biopharma Inc. and X4 Pharmaceuticals, Inc. Just below it: Enanta Pharmaceuticals, Inc., Arcturus Therapeutics Holdings Inc. and ARS Pharmaceuticals, Inc. ### Biotechnology companies close in size

1. [Alector, Inc.](https://www.sectoralpha.in/us/stocks/alec) $338 million
2. [Benitec Biopharma Inc.](https://www.sectoralpha.in/us/stocks/bntc) $324 million
3. [X4 Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/xfor) $321 million
4. Agenus Inc. $314 million
5. [Enanta Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/enta) $310 million
6. [Arcturus Therapeutics Holdings Inc.](https://www.sectoralpha.in/us/stocks/arct) $309 million
7. [ARS Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/spry) $303 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [8x8, Inc.](https://www.sectoralpha.in/us/stocks/eght) $301 million · Software - Application
2. [Idaho Strategic Resources, Inc.](https://www.sectoralpha.in/us/stocks/idr) $301 million · Gold
3. Agenus Inc. $300 million
4. [TRX Gold Corporation](https://www.sectoralpha.in/us/stocks/trx) $299 million · Gold
5. [Princeton Bancorp, Inc.](https://www.sectoralpha.in/us/stocks/bprn) $299 million · Banks - Regional

## What else do people ask about Agenus? ### What were Agenus's latest quarterly results? Agenus Inc. reported revenue of $34.5 M and a net loss of $604 K for the Jun 2026 quarter. Earnings per share were −$0.01. The operating margin was 32.7%, 98.0 percentage points higher than a year earlier (as of 4 November 2026). ### What is Agenus's market cap? Agenus Inc.'s market capitalisation is $314 M at a stock price of $6.97. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Agenus performing? Agenus Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Agenus's stock price go up? This page does not forecast Agenus Inc.'s stock price. What it shows instead: the stock price is $6.97. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is Agenus in its business cycle? Agenus Inc.'s FY25 operating margin was −18.0%, against a 5-year range of −183.9% to 12.6%: the middle of its own range, neither a peak nor a low. The latest quarter was 32.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Agenus story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Agenus a stock worth studying right now? What the numbers show: Agenus Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.